Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.

Molecular cancer - 24 Feb 2022

Kolesar Jill, Peh Spencer, Thomas Levin, Baburaj Gayathri, Mukherjee Nayonika, Kantamneni Raveena, Lewis Shirley, Pai Ananth, Udupa Karthik S, Kumar An Naveena, Rangnekar Vivek M, Rao Mahadev

Abstract excerpt

The advent of molecular profiling has revolutionized the treatment of lung cancer by comprehensively delineating the genomic landscape of the epidermal growth factor receptor (EGFR) gene. Drug resistance caused by EGFR mutations and genetic polymorphisms of drug metabolizing enzymes and transporters impedes effective treatment of EGFR mutant and resistant lung cancer. This review appraises current literature,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Lung Neoplasms

Share to Pharmacogenetics

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 35209919
DOI: 10.1186/s12943-022-01534-8
PMCID: PMC8867675

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.PMID 35209919Read ↗

Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer.Semantic proximity Read ↗

The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.Semantic proximity Read ↗

The evolving role of liquid biopsy in lung cancer.Semantic proximity Read ↗

Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancer.Semantic proximity Read ↗

Are liquid biopsies a surrogate for tissue EGFR testing?Semantic proximity Read ↗

Liquid biopsy genotyping in lung cancer: ready for clinical utility?Semantic proximity Read ↗

Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects.Semantic proximity Read ↗

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.Semantic proximity Read ↗

Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.Semantic proximity Read ↗

Liquid biopsy and its role in an advanced clinical trial for lung cancer.Semantic proximity Read ↗

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.Semantic proximity Read ↗

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.